Quick Answer
Evogene Ltd. reported R&D Expense of $7.99 million for fiscal year 2025.
Evogene Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.99M | -36.1% |
| 2024 | $12.51M | -22.8% |
| 2023 | $16.20M | -22.1% |
| 2022 | $20.79M | -1.6% |
| 2021 | $21.12M | +22.2% |
| 2020 | $17.29M | +9.5% |
| 2019 | $15.79M | +7.5% |
| 2018 | $14.69M | -13.5% |
| 2017 | $16.99M | +3.5% |
| 2016 | $16.41M | +13.5% |
| 2015 | $14.45M | — |
- Evogene Ltd. showed a decrease of -36.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Evogene Ltd.’s r&d expense has declined by 44.7% (from $14.45 million to $7.99 million).
- The most recent figure is from Evogene Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: